“If I look at R&D and SG&A kind of in aggregate, they're likely to grow at relatively similar rates next year.”

In context

“to operating expenses to drive growth in the areas of focus, and we're being focused there. We're looking to execute some opportunities to expand markets by gaining additional clinical indications and geographical clearances. And obviously, we want to advance our technology. Within SG&A, what you see in subsets of the G&A functions is us looking to pursue leverage as we've described. And generally, from an R&D perspective, there are some investments that, as Gary has previously referenced were sequencing, and that's partly motivated by the way in which headcount has expanded over, let's say, the last year or two, and we've moderated our headcount growth as described, and that gives us the opportunity to absorb some of that headcount. So there's differential investment within SG&A and R&D. If I look at R&D and SG&A kind of in aggregate, they're likely to grow at relatively similar rates next year. Robbie Marcus: Great. I appreciate you taking the questions. Operator: Then we'll go to the line of Larry Biegelsen with Wells Fargo. Please, go ahead. Larry Biegelsen: Good afternoon. Thanks for taking the question. One, on your -- Gary, your new system comments and one on the industrial scale comments that you made today at JPMorgan. So you talked about core technology changes often requiring the clinical trials and that you won't launch a multi-port system in 2023. So Gary, my question is A, will you start a clinical trial and a new system in 2023; and B, if you did start a clinical trial, would you disclose that publicly even if the trial were outside the US, say, in a developing market? Gary Guthart: Across our systems, we are doing trials in all sorts of places for all sorts of reas”